Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Eisai’s Alzheimer’s Skipper to Retire after Full Leqembi Approval
July 12, 2023
- Astellas Bags Rights to 4DMT’s Gene Therapy Vector for Eye Diseases
July 12, 2023
- Shionogi to Cut 200 Jobs via Voluntary Buyout Program
July 11, 2023
- Japan Ethical Drug Sales Up 7.2% in May: Crecon
July 10, 2023
- Full US Nod in Hand, Eisai CEO Keeps 1 Trillion Yen Sales Target for FY2030
July 10, 2023
- Pfizer, Moderna File Updated COVID-19 Vaccines in Japan
July 7, 2023
- Meiji/Zeria Grabs Thai Approval for Functional Dyspepsia Drug
July 7, 2023
- Astellas’ 1st-in-Class Gastric Cancer Med Bags Priority Review in US
July 7, 2023
- Opdivo Extends Streak of Best-Seller Title to 18 Months: Encise
July 7, 2023
- FDA Awards Full Approval to Eisai’s Alzheimer’s Drug
July 7, 2023
- Taiho’s FGFR Inhibitor Lytgobi Grabs Conditional OK in Europe
July 6, 2023
- Insmed Japan to Capitalize on Arikayce, Pins Hopes on Brensocatib: New President
July 5, 2023
- Alarmed over Domestic Generics Biz, Sawai Group to Review Long-Term Targets
July 5, 2023
- Shionogi Files Xofluza for Pediatric Indication in Taiwan
July 5, 2023
- Chugai’s Hemlibra Launched for Hemophilia A without Inhibitors in Taiwan
July 5, 2023
- Nippon Shinyaku’s DMD Drug Gets Rare Pediatric Disease Tag in US
July 5, 2023
- Jan Stefan Scheld to Helm Nippon Boehringer Ingelheim
July 5, 2023
- Eisai CEO Confident on US Full Approval for Leqembi
July 5, 2023
- Teijin, Axcelead Seal Definitive Accord to Form Drug Discovery JV
July 4, 2023
- Chugai Is Best-Paying Japan Pharma Again in FY2022, 5 Drug Makers Top 10 Million Yen
July 4, 2023
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…